Overview

Useful For
Detecting increased complement activation

Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)

NY State Available
Yes

Specimen

Specimen Type
Plasma Na Cit

Specimen Required

Patient Preparation:
1. Fasting preferred.
2. Do not collect a specimen for the 48 hours following a plasma exchange.

Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1.5 mL

Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. Centrifuge between 1000-2000 x g for 10 minutes at 4 degrees C and aliquot plasma into plastic vial.
3. Freeze specimen within 30 minutes.

Specimen Minimum Volume
0.5 mL

Reject Due To

| Gross hemolysis | OK |
| Gross lipemia   | Reject |
| Gross icterus   | OK |

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
</table>
Clinical & Interpretive

Clinical Information
The complement system membrane attack complex (MAC) is formed by the C5b fragment along with C6, C7, C8 and several C9 molecules. This complex is recognized by multiple names, including MAC, terminal complement complex and C5b-9. Laboratory tests measure the amount of soluble C5b-9 (sC5b-9) complex. The formation of C5b-9 and sC5b-9 is a consequence of activation of the complement system by either the classical, lectin, or alternative pathways. Therefore, measurement of the sC5b-9 complex can be used as a surrogate marker of terminal complement activation via all complement pathways.

Elevated concentrations of C5b-9 are associated with the development of transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic stem cell transplant.(1-3) Patients with higher sC5b-9 concentrations at baseline may require the use of higher doses of eculizumab to treat TA-TMA,(4) especially in children. Because of this association, measurement of sC5b-9 before transplant as part of a diagnostic evaluation and then repeat measurements during therapy have been proposed as tools to follow-up patients.(5) Importantly, while the elevation of sC5b-9 has shown very high sensitivity for TA-TMA, it has shown only a modest specificity, ranging from 40% to 50%, and the increased sC5b-9 may be found in other transplant complications as well as several other conditions where complement activation may occur: immune-complex disease, infection, atypical hemolytic uremic syndrome, C3 glomerulopathies, etc. A panel of complement tests, such as AHUSD / Atypical Hemolytic Uremic Syndrome Complement Panel, Serum and Plasma, may provide additional information on the extent of the complement activation, along with the information of which pathway is most dysregulated.

Reference Values
< or =250 ng/mL

Interpretation
Elevated concentrations of soluble C5b-9 suggest recent or ongoing activation of the complement system, while normal and low concentrations suggest that the complement system has not been excessively activated.

A panel of complement tests may be clinically indicated to further identify the extent of the complement activation, along with the information of which pathway is most dysregulated.

Cautions
As with all complement assays, proper sample handling is of utmost importance to ensure that the complement system is not activated before clinical testing.

Measurement of soluble C5b-9 should be ideally performed prior to treatment initiation and in the absence of therapy with complement inhibitors, such as eculizumab and ravulizumab. Complement inhibitors, such as eculizumab and ravulizumab, may affect performance of this assay.

Clinical Reference
1. Qi J, Wang J, Chen J, Su J, et al: Plasma levels of complement activation fragments C3b and sC5b-9 significantly
Test Definition: C5B9
SC5b-9 Level Terminal Complement Complex, Plasma


Performance

Method Description
Microtiter plates are coated with monoclonal antibody specific to the C9 ring of the soluble C5b-9 (sC5b-9) complex. Controls, standards, and patient samples are exposed to the plate. After washing the plate, a horseradish peroxidase-conjugated anti-sC5b-9 complex antibody is added followed by a substrate to initiate color change. (Package insert: MicroVue SC5b-9 Plus EIA Kit. Quidel Corporation; 0980EN02, 09/2021)

PDF Report
No

Day(s) Performed
Tuesday, Friday

Report Available
3 to 5 days

Specimen Retention Time
14 days

Performing Laboratory Location
Rochester

Fees & Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
Test Definition: C5B9
SC5b-9 Level Terminal Complement Complex, Plasma

- Prospective clients should contact their account representative. For assistance, contact Customer Service.

Test Classification
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
86160

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC® Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C5B9</td>
<td>SC5b-9 Complement, P</td>
<td>93244-2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC® Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>616921</td>
<td>SC5b-9 Complement, P</td>
<td>93244-2</td>
</tr>
</tbody>
</table>